What Makes the St. Gallen Trial Special
Most Swiss pilot projects to date have relied on fixed dispensing locations such as pharmacies or specialized retail outlets. St. Gallen now adds a new distribution channel: some participants can have products delivered directly to their homes. The mandatory consultation—required in Swiss trials to ensure responsible use—can now take place online if desired.
📑 Inhaltsverzeichnis
With this approach, the canton is testing the very question that will be crucial for future regulation: which distribution method reaches consumers most effectively and most successfully displaces the black market? In rural regions where the nearest dispensing location may be far away, postal delivery could fill a critical gap.
Who’s Behind It and How Large Is the Trial
The project is run by the Swiss Cannabis Research association. Scientific oversight comes from the University of Zurich and the KOF economic research center at ETH Zurich, while medical care is provided by the Arud Center for Addiction Medicine. Up to 5,000 participants can take part, with approximately 3,300 authorized to legally obtain cannabis. Forty-three of St. Gallen’s 75 municipalities are participating, many in rural areas and agglomerations.
This puts St. Gallen in a growing number of Swiss study cities and cantons testing controlled cannabis access under scientific supervision. For insight into how such a trial works in practice, see our background piece on the Swiss model of controlled distribution.
What the Research Will Examine
The focus is on the economic and social consequences of regulation. Researchers want to understand how legal access affects consumption patterns, health, and the relationship with the illegal market. Early findings from other Swiss trials suggest that non-profit, controlled sales can significantly dry up the black market without driving overall consumption up.
Context: Patchwork Rather Than Law
For now, these trials operate in a legal gray zone. The planned Cannabis Products Act (CanPG), which would transition pilot projects to permanent regulation, remains under parliamentary revision. In May 2026, the responsible commission sent the proposal back to a subcommittee for revision. Industry associations like IG Hanf Schweiz support the reworking but are calling for speed and a binding follow-up solution to prevent pilot trials from producing results that lead nowhere.
Until then, Switzerland remains a patchwork of individual, scientifically supervised projects. The St. Gallen trial, with its postal delivery option, provides a puzzle piece that no other pilot has tested before—and could demonstrate how a future legal market will actually reach its customers.
Source: IG Hanf Schweiz Newsletter (July 2026); Federal Office of Public Health overview of approved pilot trials.



































